Effect of abrocitinib on skin biomarkers in patients with moderate‐to‐severe atopic dermatitis

Abstract

Alongside improvements in clinical signs and symptoms of AD, 12 weeks of abrocitinib treatment resulted in downregulation of genes associated with inflammation, epidermal hyperplasia, and Th2 and Th22 immune responses in the skin of patients with moderate-to-severe AD.